BioArctic has, in collaboration with Eisai, identified a completely new biological target, which provides an opportunity to develop novel treatments for Alzheimer’s disease. BioArctic will have exclusive rights to utilize the results from the collaboration to develop potential antibody treatments of Alzheimer’s disease. In 2015, BioArctic and Eisai entered into an equally owned collaboration to investigate…